GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accuray Inc (NAS:ARAY) » Definitions » Sloan Ratio %
中文

Accuray (Accuray) Sloan Ratio %

: -4.65% (As of Dec. 2023)
View and export this data going back to 2007. Start your Free Trial

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Accuray's Sloan Ratio for the quarter that ended in Dec. 2023 was -4.65%.

As of Dec. 2023, Accuray has a Sloan Ratio of -4.65%, indicating the company is in the safe zone and there is no funny business with accruals.


Accuray Sloan Ratio % Historical Data

The historical data trend for Accuray's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accuray Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 1.84 -8.84 0.37 -2.53

Accuray Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.07 -1.28 -2.53 -0.25 -4.65

Competitive Comparison

For the Medical Devices subindustry, Accuray's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accuray Sloan Ratio % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Accuray's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Accuray's Sloan Ratio % falls into.



Accuray Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Accuray's Sloan Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Sloan Ratio=(Net Income (A: Jun. 2023 )-Cash Flow from Operations (A: Jun. 2023 )
-Cash Flow from Investing (A: Jun. 2023 ))/Total Assets (A: Jun. 2023 )
=(-9.28-15.539
--12.681)/479.214
=-2.53%

Accuray's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-14.547-19.823
--12.216)/476.35
=-4.65%

Accuray's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 0.599 (Mar. 2023 ) + -2.556 (Jun. 2023 ) + -2.969 (Sep. 2023 ) + -9.621 (Dec. 2023 ) = $-14.5 Mil.
Accuray's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 24.626 (Mar. 2023 ) + 8.881 (Jun. 2023 ) + -8.591 (Sep. 2023 ) + -5.093 (Dec. 2023 ) = $19.8 Mil.
Accuray's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -1.899 (Mar. 2023 ) + -7.976 (Jun. 2023 ) + -1.092 (Sep. 2023 ) + -1.249 (Dec. 2023 ) = $-12.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accuray  (NAS:ARAY) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Accuray has a Sloan Ratio of -4.65%, indicating the company is in the safe zone and there is no funny business with accruals.


Accuray Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Accuray's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Accuray (Accuray) Business Description

Traded in Other Exchanges
Address
1240 Deming Way, Madison, WI, USA, 53717
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Executives
Gina Corradetti officer: VP, Corporate Controller 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Ali Pervaiz officer: SVP Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Jesse Chew officer: SVP and General Counsel 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sandeep Chalke officer: SVP, Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Suzanne C Winter officer: SVP & Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Patrick Spine officer: SVP, Chief Admin Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Michael Hoge officer: Senior VP Global Operations 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Kill director VIRTUAL RADIOLOGIC CORPORATION, 5995 OPUS PARKWAY, SUITE 200, MINNETONKA MN 55343
Brandon W Green officer: Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Franco N Palomba officer: VP, Chief Accounting Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Byron C Scott director 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joshua Levine officer: President & CEO 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Joseph E Whitters director
Shigeyuki Hamamatsu officer: VP, Finance and CAO 1875 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043